Cogstate Launches New Investor Hub
Released
Released
Announcement PDF
ASX Announcement
13 June 2025
Cogstate Launches New Investor Hub
Cogstate Ltd (ASX:CGS) is pleased to announce the launch of its new InvestorHub, designed to provide
shareholders with improved access to announcements, company updates, strategic insights, and key information.
From its foundation delivering highly sensitive, standardised digital cognitive assessments, Cogstate is today an
essential partner for pharmaceutical and biotech companies worldwide, powering advanced clinical research with
evidence-backed technology that delivers unprecedented accuracy and operational efficiency.
Having transitioned to strong revenue, profit and cash growth over the last five years, Cogstate is uniquely
positioned at the intersection of increasing investment in R&D in Central Nervous System (CNS) diseases,
advanced data analytics, and artificial intelligence.
“As pharmaceutical and biotech companies intensify their focus on neurodegenerative drug development pipelines,
Cogstate is poised to capture significant growth opportunities over the next five years and beyond by empowering
partners to deliver faster, more reliable, and more innovative clinical research,” said Cogstate CEO Brad O’Connor.
“With Cogstate entering this next exciting phase our new InvestorHub will elevate our engagement with our
shareholders and provide a platform to engage actively with new investors.”
Launch of Cogstate Investor Insight Series
Cogstate is today launching its Investor Insight Series via the InvestorHub platform, a series of virtual and inperson events across Australia and the US designed to expand investor reach, elevate the positioning and
understanding of Cogstate, and engage a broader investor community.
Please join us at our first event a webinar to showcase the dynamic partnership between Cogstate and Medidata,
two leaders in clinical trial technology and cognitive assessment.
Investor participants will gain insights into the transformative impact of this collaboration on CNS disease research
and learn how the alliance is accelerating innovation and improving trial outcomes. Featuring Medidata CEO
Anthony Costello, the session will highlight Medidata’s industry-leading platform, Cogstate’s expertise in cognitive
and clinical assessment, and the combined value they bring to sponsors, researchers, and patients.
Driving Innovation in CNS Trials: The Cogstate-Medidata Partnership and the Future of Central Nervous
System Research.
Wednesday, 25 June 2025 at 9:00am AEST (Tuesday, 24 June 2025 at 7:00pm US EST)
Register online for the webinar and InvestorHub via this link: https://investors.cogstate.com/webinars/7PR1Xrdriving-innovation-in-cns-trials-the-cogstate-medidata-partnership
| Page 1
View InvestorHub
Cogstate’s new InvestorHub will regularly upload new content including videos, key project news and updates.
Watch CEO Brad O’Connor’s introduction to Cogstate’s InvestorHub here.
We invite shareholders and interested parties to sign up to the InvestorHub and create an account to post
questions/feedback to engage with the leadership team and gain a better understanding of the company’s updates.
This announcement was authorised for release by Cogstate Ltd CEO, Brad O’Connor.
About Cogstate
Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the
development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable
and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome
assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company’s
clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches,
advanced analytics and scientific consulting. For over 20 years, Cogstate has proudly supported the leading-edge research needs
of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world.
In the Healthcare market, Cogstate seeks to provide primary care physicians and consumers with brief, accurate and scientifically
validated digital measures of cognition, with a focus on easy to use, self-administered tests that inform patients and save physician
time. In this market, Cogstate has partnered with pharmaceutical company, Eisai, to distribute Cogstate assessments in Asia.
For more information, please visit www.cogstate.com.
For further information contact:
Brad O’Connor, Chief Executive Officer, boconnor@cogstate.com
| Page 2
Share your feedback
Discover